1. Scrip
  2. >>R&D
  3. >>Clinical Trials

WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention

Longer-Term MARIPOSA Results For J&J’s EGFR Drug Combo

 
• By Mandy Jackson

Highlights will include data for Summit/Akeso’s PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.

Holographic concept of lung cancer display, lung disease, treatment of lung cancer, lung illness
The WCLC starts on 7 September in San Diego • Source: Shutterstock

The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including rising interest in bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs), in lung cancers.

Key Takeaways

  • The World Conference on Lung Cancer (WCLC) meeting 7-10 September in San Diego will highlight new directions in treatment, including antibody-drug conjugates and bispecifics.

  • AstraZeneca/Daiichi Sankyo’s TROP2-targeting ADC Dato-DXd will have multiple readouts in non-small cell lung cancer ahead of its potential second-line approval in the US in late 2024

The approval of Amgen, Inc.’s DLL3-targeting BiTE Imdelltra (tarlatamab) in small-cell lung cancer (SCLC) and the pending US Food and Drug Administration approval decision for AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Trop-2-targeting ADC datopotomab deruxtecan (Dato-DXd) in non-small cell lung cancer (NSCLC), due by 20 December, are prime examples of changes happening in the treatment landscape

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

More from R&D

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.